A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Benralizumab|DRUG: fulvestrant or AIs) and PI3K inhibition (alpelisib)
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: AstraZeneca|Novartis Pharmaceuticals